Table 6.
The number of cases using certain ACSS thresholds for clinical success at Day 5/6 in the patients of the US (n = 100) and international group at Day 5–9 (end of treatment) (n = 82) [10]. Note: each case with any “visible blood in the urine (VBU)” at end of treatment was rated “non-success”.
| Type | Thresholds for Clinical Success | American English | International |
|---|---|---|---|
| A | Sum score of typical domain ≤5 scores, no item >1 | 91 (91%) | 66 (80.49%) |
| B | Sum score of typical domain ≤5 scores, no item >1 and no item of QoL >1 | 91 (91%) | 60 (73.17%) |
| C | Dynamics, no item >1 | 91 (91%) | 64 (78.05%) |
| D | Sum score of the 4 FDA symptoms ≤4, no item >1 | 91 (91%) | 66 (80.49%) |
| E | Sum score of the 3 EMA symptoms ≤3, no item>1 | 91 (91%) | 67 (81.71%) |
4 FDA symptoms (urinary frequency, urinary urgency, dysuria, suprapubic pain). 3 EMA symptoms (urinary frequency, urinary urgency, dysuria).